Skip to main content

March 2020, Vol 10, No 3

Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent. Luspatercept-aamt (Reblozyl), a recombinant fusion protein that binds transforming growth factor beta superfamily ligands to reduce SMAD2 and SMAD3 signaling, was approved by the FDA in November 2019 and has been studied in this patient population with promising results.

Read Article ›

The discontinuation of oral oncology medications before the full-month supply has been finished results in medication waste, leading to increased costs for patients and for payers. Split fills allow for a 14- to 16-day supply for oral oncology medications rather than a full 28- to 30-day supply. Researchers compared the discontinuation rates, patient-reported adverse events, estimated pharmacy costs, and potential waste in patients with pharmacy benefit designs that included a split-fill option with patients who did not have this option (Staskon FC, et al. J Oncol Pract. 2019;15:e856-e862).

Read Article ›

Patient navigation is an increasingly recognized component of high-quality, patient-centered care. However, patient navigation in cancer programs is limited, often because of uncertainty about sustainable financial models to support these programs and defining the scope of practice. To demonstrate the benefits of patient navigation programs, researchers analyzed 5 real-world case studies (Kline RM, et al. J Oncol Pract. 2019;15:585-590).

Read Article ›

Page 2 of 2